A Calgary-based company, Solvet, has received emergency use authorization from the U.S. Food and Drug Administration (FDA) to sell its equine ivermectin product in the United States to combat screwworm. Solvet’s CEO, Lionel Gibbs, highlighted the unique qualities of their aqueous-based solution, which is more concentrated and easier to administer than traditional paste formulations.
Founded in 2009 by former University of Calgary professors, Solvet has become one of Canada’s leading veterinary pharmaceutical companies. Ivermectin, known for its effectiveness against various parasites, including screwworm, has played a crucial role in livestock health. Screwworm, a fly species native to North America, poses a significant threat to animals as its larvae feed on tissue, leading to severe pain, infections, and potentially death.
Historically, screwworm infestations have caused substantial economic losses to ranchers in the U.S. and Mexico. The eradication efforts in North America utilized a sterile insect technique, effectively eliminating screwworm populations. However, recent reports of screwworm resurgence in Central America and Mexico, spreading towards the southern U.S., have raised concerns.
In response to the screwworm resurgence, Solvet’s ivermectin product has been granted emergency authorization for specific use against screwworm in the U.S. The FDA’s decision aims to protect livestock and food supplies in affected regions. While the product is labeled for broader parasite control in Canada, its U.S. authorization is limited to combatting screwworm.
Experts like John Gilleard, a veterinarian and parasitologist, support the authorization as a preventive measure to safeguard animals at risk. However, the responsible use of ivermectin is crucial to avoid resistance development in parasites. Despite the low risk of screwworm in Canada due to its climate, authorities continue to monitor the situation closely and collaborate with U.S. counterparts.
For Solvet, this development not only underscores its commitment to animal welfare but also presents a significant opportunity for expansion into the U.S. market. The company’s proactive response to the screwworm crisis demonstrates its potential for growth and contribution to Alberta’s economy through research and innovation.